1. Home
  2. Analysis
  3. Abilify
  4. Xigduo-xr

Abilify and Xigduo xr drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 9 people who take Abilify and Xigduo xr. Common interactions include diabetic ketoacidotic hyperglycaemic coma among females, and anxiety among males.

The phase IV clinical study analyzes what interactions people who take Abilify and Xigduo xr have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

What are phase IV trials?

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 24, 2023

9 people who take Abilify and Xigduo xr together, and have interactions are studied.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is used in depression. Currently, eHealthMe is studying from 98,584 Abilify users.

What is Xigduo xr?

Xigduo xr has active ingredients of dapagliflozin propanediol; metformin hydrochloride. Currently, eHealthMe is studying from 2,589 Xigduo xr users.

Number of Abilify and Xigduo xr reports submitted per year:

Abilify and Xigduo xr drug interactions.

Common Abilify and Xigduo Xr drug interactions by gender *:

female:

  1. Diabetic ketoacidotic hyperglycaemic coma
  2. Anxiety
  3. Decreased appetite
  4. Diabetes mellitus
  5. Sleep apnoea syndrome
  6. Weight decreased
  7. Diabetic foot
  8. Fungal infection
  9. Pneumonia

male:

  1. Anxiety
  2. Anhedonia
  3. Osteonecrosis
  4. Bone density decreased
  5. Chronic kidney disease
  6. Emotional distress
  7. Hip arthroplasty
  8. Multiple fractures
  9. Nephropathy
  10. Pain

Common Abilify and Xigduo Xr drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Anxiety

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Anhedonia
  2. Anxiety
  3. Renal impairment
  4. Osteonecrosis
  5. Pneumonia
  6. Bone density decreased
  7. Chronic kidney disease
  8. Diabetic ketoacidotic hyperglycaemic coma
  9. Emotional distress
  10. Hip arthroplasty

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and Xigduo xr?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Abilify side effects:

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xigduo xr side effects:

Browse all side effects of Xigduo xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Abilify interactions:

Browse all interactions between Abilify and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xigduo xr interactions:

Browse all interactions between Xigduo xr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole and dapagliflozin propanediol; metformin hydrochloride (the active ingredients of Abilify and Xigduo xr, respectively), and Abilify and Xigduo xr (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Abilify and Xigduo xr.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.